Clinical trial discovery
Find Clinical Trials
Search studies by condition, treatment, location, eligibility, or trial identifier.
Showing 1–19 of 19 trials
Active filters
Clinical trials found
Published and searchable clinical trials
Searching for clinical trials...
NCT05538091
- Conditions
- Hedgehog Inhibitor, PARP Inhibitor, Platinum-Resistant Fallopian Tube Carcinoma, +1 more
- Locations
-
- UPMC Hillman Cancer Center Pittsburgh, Pennsylvania, United States
Recruiting
ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
NCT04055649
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +24 more
- Locations
-
- Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States
- Karmanos Cancer Institute at McLaren Flint Flint, Michigan, United States
NCT06730347
- Conditions
- Clear Cell Adenocarcinoma of Cervix, Clear Cell Adenocarcinoma of Fallopian Tube, Clear Cell Adenocarcinoma of Ovary, +20 more
- Locations
-
- UCLA Los Angeles, California, United States
- Ochsner MD Anderson Cancer Center New Orleans, Louisiana, United States
- START Midwest Grand Rapids, Michigan, United States
- West Penn Allegheny Health Pittsburgh, Pennsylvania, United States
NCT06483048
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +30 more
- Locations
-
- Mayo Clinic in Arizona Scottsdale, Arizona, United States
Not Yet Recruiting
Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer
NCT06867562
- Conditions
- Platinum Resistant High Grade Epithelial Ovarian Cancer, Platinum Resistant High Grade Serous Ovarian Cancer, Platinum-Resistant Primary Peritoneal Carcinoma
- Locations
-
Not specified
Completed
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
NCT05483933
- Conditions
- Adnexal Diseases, Carcinoma, Carcinoma, Ovarian Epithelial, +25 more
- Locations
-
- University of Arkansas for Medical sciences Little Rock, Arkansas, United States
- City of Hope Duarte, California, United States
- Robert H.Lurie ComprehensiveCancer Center, Northwestern University Chicago, Illinois, United States
- START Midwest Grand Rapids, Michigan, United States
NCT03026062
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +23 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
NCT03508570
- Conditions
- Abdominal Neoplasms, Adnexal Diseases, Digestive System Diseases, +58 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
NCT03206047
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +20 more
- Locations
-
- Banner University Medical Center - Tucson Tucson, Arizona, United States
- University of Arizona Cancer Center-North Campus Tucson, Arizona, United States
- City of Hope Comprehensive Cancer Center Duarte, California, United States
- University of California Davis Comprehensive Cancer Center Sacramento, California, United States
NCT02020707
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosarcoma, Cervical Adenosquamous Carcinoma, +45 more
- Locations
-
- Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
- Mayo Clinic in Arizona Scottsdale, Arizona, United States
- Mayo Clinic in Florida Jacksonville, Florida, United States
- Mayo Clinic in Rochester Rochester, Minnesota, United States
- Conditions
- Breast Diseases, Breast Neoplasms, Metastatic High Grade Fallopian Tube Serous Adenocarcinoma, +27 more
- Locations
-
- Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
- Mayo Clinic in Arizona Scottsdale, Arizona, United States
- Mayo Clinic in Florida Jacksonville, Florida, United States
- Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States
NCT04753216
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +23 more
- Locations
-
- Northwestern University Chicago, Illinois, United States
Active, Not Recruiting
PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
NCT05465941
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +20 more
- Locations
-
- Mayo Clinic Rochester, Minnesota, United States
Active, Not Recruiting
Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors
NCT04616534
- Conditions
- Adnexal Diseases, Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, +40 more
- Locations
-
- National Cancer Institute Developmental Therapeutics Clinic Bethesda, Maryland, United States
- National Institutes of Health Clinical Center Bethesda, Maryland, United States
- Dana-Farber Cancer Institute Boston, Massachusetts, United States
Active, Not Recruiting
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
NCT02650986
- Conditions
- Adnexal Diseases, Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, +78 more
- Locations
-
- Roswell Park Cancer Institute Buffalo, New York, United States
Active, Not Recruiting
Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT03587311
- Conditions
- Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, +5 more
- Locations
-
- UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
- UCHealth University of Colorado Hospital Aurora, Colorado, United States
- UM Sylvester Comprehensive Cancer Center at Coral Gables Coral Gables, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach Deerfield Beach, Florida, United States
Active, Not Recruiting
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
NCT05271318
- Conditions
- Adenoviridae Infections, DNA Virus Infections, Infections, +10 more
- Locations
-
- Mayo Clinic Rochester, Minnesota, United States
- Northwell Heatlh/Lenox Hill Hospital New York, United States
- Docrates Cancer Center Helsinki, Finland
Active, Not Recruiting
Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT04781088
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +24 more
- Locations
-
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
- Allegheny Health Network Pittsburgh, Pennsylvania, United States
Active, Not Recruiting
Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT03907527
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +48 more
- Locations
-
- National Institutes of Health (NIH) Bethesda, Maryland, United States
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States